Latest Headlines

Latest Headlines

Otsuka, Lundbeck bag blockbuster FDA approval for antipsychotic Rexulti

Otsuka is facing plenty of bleeding, now that its blockbuster antipsychotic Abilify has generic competition. But the company is working hard to soften the blow, and a brand-new FDA approval for a long-acting antipsychotic could help.

As schizophrenia rivals rush in, Otsuka and Lundbeck gain FDA OK for Rexulti

Otsuka and its partner Lundbeck snagged an FDA approval for Rexulti (brexpiprazole) to treat schizophrenia and as an add-on therapy for major depression, leaving the two companies prepping for an August launch into an increasingly crowded field.

Has Lundbeck failed to sharpen Brintellix's marketing edge with payers?

Lundbeck's new CEO Kåre Schultz just wrapped up his first month on the job, and chances are he's brainstorming about how to jump-start the company's Brintellix launch. And as Forbes ' John LaMattina notes, the answer might lie with payers.

Lundbeck's EU lobbying yields political boost for anti-alcohol med Selincro

Last month, the European Parliament voted to push the European Commission to take a harder stance on curbing alcohol's harmful health effects. And Lundbeck, which markets alcoholism drug Selincro, did its part to make that happen.

Lundbeck bags Novo exec Schultz to engineer a much-needed turnaround

Mystery solved: Novo Nordisk heir apparent Kåre Schultz didn't just up and leave the Danish drugmaker. He left for the top job at crosstown colleague Lundbeck, vacant since that CEO stepped down in disgrace in November.

Jeremy Levin's back, building a rare-disease biotech with failed drugs

Former Teva CEO Jeremy Levin has taken the pilot's seat at a stealth biotech devoted to rare brain diseases and is piloting a course straight into the industry spotlight.

Lundbeck pulls the plug on its fast-tracked stroke drug

Lundbeck is giving up on its efforts to develop desmoteplase as a treatment for stroke, as disappointing data have made it unclear just how to proceed.

Lundbeck strikes positive note with NICE nod for alcoholism med Selincro

Here's some good news for Lundbeck in an otherwise bleak week: The U.K.'s cost watchdog has endorsed its alcohol-dependence treatment, Selincro.

Lundbeck CEO booted for ethics breach after a biotech's 'gift' comes to light

Last year Lundbeck CEO Ulf Wiinberg got a "gift" of some shares in a biotech called Stratified Medical, a London-based company that bills itself as a partner that can help drug developers more efficiently develop new therapies. And after the gift arrived, Lundbeck invested 19 million Danish krone--a little more than $3 million--into the company.

Lundbeck CEO exits in disgrace, endangering key new launches

You breach your company's code of conduct, you're out of the CEO's chair--at least, if you're Lundbeck CEO Ulf Wiinberg. The Danish drugmaker's chief is packing his bags after failing to follow procedures on stock ownership.